logo.png
  • googlePlaces
  • twitter
  • linkedin
  • Home

  • Team

  • Portfolio

  • Blog

  • Contact

  • Investors

    • MCPF I
    • MCPF II
    • Opportunity Fund
    • MCPF III
  • More

    Use tab to navigate through the menu items.

    Our Recent Posts

    Catalyst OrthoScience Announces Todd Wilson, PhD as Vice President of Medical Education & Training

    Real-world study of SPRINT Corroborates Published Clinical Study Results

    7SIGNAL Hires New Chief Technology Officer

    Archive

    • May 2022
    • April 2022
    • March 2022
    • January 2022
    • December 2021
    • October 2021
    • September 2021
    • August 2021
    • June 2021
    • May 2021
    • April 2021
    • February 2021
    • January 2021
    • December 2020
    • November 2020
    • October 2020
    • July 2020
    • April 2020
    • March 2020
    • February 2020
    • January 2020
    • December 2019
    • October 2019
    • September 2019
    • August 2019
    • July 2019
    • June 2019
    • May 2019
    • April 2019
    • March 2019
    • February 2019
    • January 2019
    • December 2018
    • November 2018
    • October 2018
    • September 2018
    • August 2018
    • July 2018
    • June 2018
    • May 2018
    • March 2018
    • February 2018
    • January 2018
    • December 2017
    • November 2017
    • October 2017
    • September 2017
    • August 2017
    • July 2017
    • June 2017
    MCP Invests in SPR Therapeutics' $37 Million Growth Equity Financing

    MCP Invests in SPR Therapeutics' $37 Million Growth Equity Financing

    SPR Therapeutics, a private medical device company focused on providing patients with pain relief without opioids or surgery, announced today it has raised $37 million in an oversubscribed Series D growth equity financing. The investment will be used to accelerate the rapidly growing commercial uptake of its FDA-cleared SPRINT® Peripheral Nerve Stimulation (PNS) System, to fund additional clinical research, and to advance next generation technology. SPR’s SPRINT PNS System is
    Catalyst Orthoscience Announces $12.3 Million Oversubscribed Financing

    Catalyst Orthoscience Announces $12.3 Million Oversubscribed Financing

    Catalyst OrthoScience Inc. (Catalyst), a medical device company focused on the upper extremity orthopedics market, has raised $12.3 million in an oversubscribed Series D financing round led by River Cities Capital (River Cities) and Mutual Capital Partners (Mutual Capital). “This funding round comes at a pivotal time for the Catalyst OrthoScience team,” said Brian K. Hutchison, chairman and CEO of Catalyst. “We are experiencing a significant period of growth, and this fundin

    MCP Leads Financing in Redi.Health

    Redi.Health, provider of health management technology that improves total patient health, is announcing it has secured seed funding, led by Cleveland, Ohio-based Mutual Capital Partners (MCP), to broaden the development and availability of its novel platform that improves daily health management for polychronic patients. The financing is supported with additional investment from M25, Rev1 Ventures and Plug and Play. The population of polychronic patients (those with three or

     Follow us:

    • googlePlaces
    • twitter
    • linkedin

    Email us:

    Mutual Capital Partners

    1290 Bassett Rd  Suite #7

     Westlake, OH 44145

    MCPF@mutualcapitalpartners.com

    ©2021 by Mutual Capital Partners